451 related articles for article (PubMed ID: 25814214)
1. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.
Yamagishi S; Fukami K; Matsui T
Int J Cardiol; 2015 Apr; 185():263-8. PubMed ID: 25814214
[TBL] [Abstract][Full Text] [Related]
2. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
3. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
[TBL] [Abstract][Full Text] [Related]
4. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
Yamagishi S
Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
[TBL] [Abstract][Full Text] [Related]
5. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
6. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention.
Yamagishi S; Matsui T
Nutrition; 2016 Feb; 32(2):157-65. PubMed ID: 26602289
[TBL] [Abstract][Full Text] [Related]
7. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.
Yamagishi SI; Nakamura N; Matsui T
J Diabetes; 2017 Feb; 9(2):141-148. PubMed ID: 27556881
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
Yamagishi S
Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
[TBL] [Abstract][Full Text] [Related]
9. [Bone metabolism and cardiovascular function update. Impairment of osteo-vascular interaction by glyco-oxidative stress].
Yamagishi SI
Clin Calcium; 2014 Jul; 24(7):85-91. PubMed ID: 24976060
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.
Yamagishi S; Fukami K; Matsui T
Cardiovasc Diabetol; 2015 Jan; 14():2. PubMed ID: 25582643
[TBL] [Abstract][Full Text] [Related]
11. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
Yamagishi S; Nakamura K; Matsui T
Pharmacol Res; 2009 Sep; 60(3):174-8. PubMed ID: 19646657
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.
Jiang J; Chen P; Chen J; Yu X; Xie D; Mei C; Xiong F; Shi W; Zhou W; Liu X; Sun S; Zhang P; Yang X; Zhang Y; Zhang Y; Liang X; Zhang Z; Lin Q; Yu Y; Miyata T; Tian J; Liang M; Luo W; Xu X; Hou F
Atherosclerosis; 2012 Sep; 224(1):187-94. PubMed ID: 22857897
[TBL] [Abstract][Full Text] [Related]
13. [Diabetic macrovascular complications].
Yamagishi S
Nihon Rinsho; 2015 Mar; 73(3):479-83. PubMed ID: 25812377
[TBL] [Abstract][Full Text] [Related]
14. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease.
Smit AJ; Gerrits EG
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):527-33. PubMed ID: 20844429
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review.
Arsov S; Graaff R; van Oeveren W; Stegmayr B; Sikole A; Rakhorst G; Smit AJ
Clin Chem Lab Med; 2014 Jan; 52(1):11-20. PubMed ID: 23612551
[TBL] [Abstract][Full Text] [Related]
16. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
Yamagishi S; Taguchi K; Fukami K
Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.
Yamagishi S; Matsui T; Nakamura K
Med Hypotheses; 2008 Nov; 71(5):749-51. PubMed ID: 18710793
[TBL] [Abstract][Full Text] [Related]
18. Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes.
Rigalleau V; Cougnard-Gregoire A; Nov S; Gonzalez C; Maury E; Lorrain S; Gin H; Barberger-Gateau P
J Diabetes Complications; 2015 Mar; 29(2):270-4. PubMed ID: 25468311
[TBL] [Abstract][Full Text] [Related]
19. Skin autofluorescence advanced glycosylation end products as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients.
Nongnuch A; Davenport A
Nephrology (Carlton); 2015 Nov; 20(11):862-7. PubMed ID: 26014842
[TBL] [Abstract][Full Text] [Related]
20. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H
Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
